Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H P Sinn

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Der Radiologe|November 12, 2005
[Neoadjuvant chemotherapy of breast carcinomas: what post-therapeutic (preoperative) information is provided by quantitative dynamic MRI?]K Wasser, S K Klein, H Junkermann, et al.
International Journal of Cancer|February 8, 1995
Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancerP Dall, K H Heider, H P Sinn, et al.
European Radiology|May 24, 2003
Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapyK Wasser, H P Sinn, C Fink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challengesJ Heil, H M Kuerer, A Pfob, et al.
Intensive Care Medicine|November 1, 1996
Benefits of various dextrans after delayed therapy in necrotizing pancreatitis of the ratJ Schmidt, K Huch, K Mithöfer, et al.
International Journal of Cancer|March 10, 2001
Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinomaT Schilling, J Bürck, H P Sinn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2010
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancerA Schneeweiss, F Marmé, A Ruiz, et al.
International Journal of Cancer|June 8, 2001
Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patientsA Seute, H P Sinn, R F Schlenk, et al.
The Journal of Pathology|December 18, 2001
Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patternsW Boecker, H Buerger, K Schmitz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II studyA Schneeweiss, J Huober, H-P Sinn, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Der Radiologe|November 12, 2005
[Neoadjuvant chemotherapy of breast carcinomas: what post-therapeutic (preoperative) information is provided by quantitative dynamic MRI?]K Wasser, S K Klein, H Junkermann, et al.
International Journal of Cancer|February 8, 1995
Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancerP Dall, K H Heider, H P Sinn, et al.
European Radiology|May 24, 2003
Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapyK Wasser, H P Sinn, C Fink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challengesJ Heil, H M Kuerer, A Pfob, et al.
Intensive Care Medicine|November 1, 1996
Benefits of various dextrans after delayed therapy in necrotizing pancreatitis of the ratJ Schmidt, K Huch, K Mithöfer, et al.
International Journal of Cancer|March 10, 2001
Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinomaT Schilling, J Bürck, H P Sinn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2010
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancerA Schneeweiss, F Marmé, A Ruiz, et al.
International Journal of Cancer|June 8, 2001
Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patientsA Seute, H P Sinn, R F Schlenk, et al.
The Journal of Pathology|December 18, 2001
Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patternsW Boecker, H Buerger, K Schmitz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II studyA Schneeweiss, J Huober, H-P Sinn, et al.
Pageof 8